Alpine Immune Sciences (NASDAQ:ALPN) Reaches New 52-Week High at $45.44

Shares of Alpine Immune Sciences, Inc. (NASDAQ:ALPN - Get Free Report) hit a new 52-week high on Wednesday . The company traded as high as $45.44 and last traded at $42.96, with a volume of 3580009 shares trading hands. The stock had previously closed at $38.94.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on ALPN. Oppenheimer restated an "outperform" rating and issued a $44.00 target price (up previously from $33.00) on shares of Alpine Immune Sciences in a research note on Tuesday, March 19th. HC Wainwright boosted their price target on Alpine Immune Sciences from $32.00 to $50.00 and gave the stock a "buy" rating in a research report on Tuesday, March 19th. Wedbush reaffirmed an "outperform" rating and issued a $47.00 price target on shares of Alpine Immune Sciences in a research report on Tuesday, March 19th. Wolfe Research began coverage on Alpine Immune Sciences in a research report on Thursday, February 15th. They set an "outperform" rating and a $44.00 price objective for the company. Finally, Morgan Stanley boosted their price objective on Alpine Immune Sciences from $30.00 to $47.00 and gave the stock an "overweight" rating in a research report on Tuesday, March 19th. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Alpine Immune Sciences has a consensus rating of "Buy" and a consensus price target of $40.88.

Alpine Immune Sciences Stock Performance

The company has a market capitalization of $3.08 billion, a P/E ratio of -73.50 and a beta of 1.14. The firm has a 50 day moving average price of $34.96 and a two-hundred day moving average price of $22.30.

Alpine Immune Sciences (NASDAQ:ALPN - Get Free Report) last released its quarterly earnings results on Monday, March 18th. The biotechnology company reported $0.15 EPS for the quarter, topping analysts' consensus estimates of ($0.32) by $0.47. The business had revenue of $30.85 million for the quarter, compared to analyst estimates of $6.90 million. Alpine Immune Sciences had a negative return on equity of 15.54% and a negative net margin of 54.66%. On average, equities analysts expect that Alpine Immune Sciences, Inc. will post -1.76 earnings per share for the current year.

Institutional Investors Weigh In On Alpine Immune Sciences

Large investors have recently bought and sold shares of the business. Royal Bank of Canada grew its position in Alpine Immune Sciences by 99.1% during the 2nd quarter. Royal Bank of Canada now owns 2,642 shares of the biotechnology company's stock worth $27,000 after acquiring an additional 1,315 shares during the last quarter. Allspring Global Investments Holdings LLC grew its position in Alpine Immune Sciences by 745.5% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,488 shares of the biotechnology company's stock worth $28,000 after acquiring an additional 1,312 shares during the last quarter. Public Employees Retirement System of Ohio acquired a new position in Alpine Immune Sciences during the 3rd quarter worth $35,000. Barclays PLC lifted its holdings in Alpine Immune Sciences by 818.4% during the 4th quarter. Barclays PLC now owns 6,080 shares of the biotechnology company's stock worth $45,000 after buying an additional 5,418 shares in the last quarter. Finally, BNP Paribas Arbitrage SNC lifted its holdings in Alpine Immune Sciences by 88.7% during the 3rd quarter. BNP Paribas Arbitrage SNC now owns 6,572 shares of the biotechnology company's stock worth $47,000 after buying an additional 3,090 shares in the last quarter. 75.17% of the stock is currently owned by institutional investors.

Alpine Immune Sciences Company Profile

Alpine Immune Sciences, Inc operates as a clinical-stage immunotherapy company. It focuses on creating various immunotherapies through protein engineering technologies for autoimmune and inflammatory diseases. The company has strategic collaborations with biopharmaceutical companies and has a pipeline of clinical and preclinical candidates in development.